Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07508722 · ClinicalTrials.gov registry record · NA

Transcranial Ultrasonic Neuromodulation of Primary Visual Cortex and Primary Auditory Cortex in Humans

A NA study, sponsored by Massachusetts Institute of Technology.

Not yet
Registry status
NA
Development phase
20
Enrollment target

NCT07508722: Clinical Trial NA study, sponsored by Massachusetts Institute of Technology.

NCT07508722 is a NA study that has not yet begun recruiting, run by Massachusetts Institute of Technology. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07508722, a NA study, has not yet begun recruiting, sponsored by Massachusetts Institute of Technology.

NOT YET RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

There are a number of disorders of the brain that have limited treatment options, such as chronic pain, addiction, and major depression. A new technology has emerged in the last decade known as transcranial focused ultrasound, which can deliver focused acoustic signals through the skull to modulate brain activity over a small region, including structures deep in the brain. This has resulted in many ongoing clinical trials for various disorders, but there is still a lack of understanding of the optimal sonication parameters for increasing versus decreasing brain activity. The investigators aim to address this open question by sonicating the primary visual cortex and primary auditory cortex in human with a range of sonication parameters. These brain structures were chosen to target because they are expected to elicit perceptual responses in the subject (i.e., the subject will report visual and auditory perception during sonication), allowing the experimenters to infer directly the extent to which neural signals can propagate through the visual and auditory systems in a way that is sufficient to produce conscious perception. Such findings have applications not only in clinical treatments, but also in the fundamental science of the neural basis of sensory perception. Previous work has shown that sonicating the visual cortex in humans can elicit visual perception, but the ultrasonic system in prior work did not have the focusing capabilities that will be employed in this study. At the end of this study, the investigators will have determined the optimal sonication parameters that can elicit neural responses over a small volume over sensory cortex, which can be inferred from visual percepts being localized in space (e.g., a bright spot as opposed to a diffuse light), and auditory percepts that sound like pure tones rather than a broad set of frequencies (e.g., sounding like white noise or static).

Primary Outcome

Change in peak-to-peak amplitude (µV) of sensory-evoked potentials recorded from scalp electroencephalography (EEG) over the targeted cortical region (visual or auditory cortex, depending on stimulation condition) during and after transcranial focused ultrasound stimulation, relative to baseline (pre-stimulation).

Interventions

  • DEVICE Magnetic Resonance Imaging
  • DEVICE Transcranial Focused Ultrasound Stimulation
  • DEVICE Electroencephalography

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-10-01
Est. Completion 2027-06-01
Phase NA

What is known before NCT07508722 opens enrollment

NCT07508722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.

NCT07508722 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07508722 about?

NCT07508722 is a clinical study titled "Transcranial Ultrasonic Neuromodulation of Primary Visual Cortex and Primary Auditory Cortex in Humans". There are a number of disorders of the brain that have limited treatment options, such as chronic pain, addiction, and major depression. A new technology has emerged in the last decade known as transcranial focused ultrasound, which can deliver focused acoustic signals through the skull to modulate ...

What is the current status of trial NCT07508722?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-10-01. Estimated completion is 2027-06-01.

What interventions are being tested in trial NCT07508722?

The interventions under investigation include: Magnetic Resonance Imaging (DEVICE), Transcranial Focused Ultrasound Stimulation (DEVICE), Electroencephalography (DEVICE).

Who is sponsoring clinical trial NCT07508722?

This trial is sponsored by Massachusetts Institute of Technology, which has 24 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07508722's enrollment target sits among peer trials

20 1768th of 2000 higher than 140 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07508722, the US trial registry maintained by the National Library of Medicine. NCT07508722 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.